Kairos Pharma Receives Clinical Trials Arena Award for Prostate Cancer Research

Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company, has been recognized with the 2025 Clinical Trials Arena Excellence Awards, specifically receiving the Research and Development Award for Advanced Prostate Cancer. This accolade underscores the company's progress in developing ENV-105 (carotuximab), a first-in-class CD105-targeting monoclonal antibody designed to combat treatment resistance in metastatic castration-resistant prostate cancer (mCRPC). The award is based on positive interim safety and efficacy data from a Phase 2 randomized clinical trial evaluating ENV-105 in combination with apalutamide.

The significance of this recognition lies in the urgent need for new therapies in advanced prostate cancer, particularly for patients who develop resistance to standard treatments. Metastatic castration-resistant prostate cancer represents a challenging stage of the disease where tumors continue to grow despite hormone therapy, leading to limited treatment options and poor outcomes. Kairos Pharma's approach targets CD105, a protein identified as a key driver of resistance to various cancer therapies. According to the company, elevation of CD105 in response to standard treatment contributes to resistance and disease relapse, making it a critical therapeutic target.

ENV-105 aims to reverse drug resistance by targeting CD105, potentially restoring the effectiveness of standard therapies across multiple cancer types. Currently, the drug candidate is being investigated in a Phase 2 clinical trial for castrate-resistant prostate cancer and a Phase 1 trial for lung cancer, addressing significant unmet medical needs in oncology. The company's research strategy utilizes structural biology to overcome drug resistance and immune suppression in cancer, positioning its work at the forefront of oncology therapeutics.

The implications of this award and the underlying research extend beyond academic recognition. For patients with advanced prostate cancer, the development of ENV-105 represents a potential new treatment avenue that could improve survival and quality of life. For the pharmaceutical industry, success with this novel mechanism could validate CD105 as a viable target for other resistant cancers, potentially leading to broader therapeutic applications. The recognition by Clinical Trials Arena also highlights the growing importance of targeted therapies that address specific resistance mechanisms, rather than simply attacking cancer cells through traditional cytotoxic approaches.

Investors and stakeholders can access additional information through the company's newsroom at https://ibn.fm/KAPA. The broader context of this announcement involves the specialized communications platform InvestorWire, which facilitates press release syndication and corporate communications for public and private companies. More details about this platform are available at https://www.InvestorWire.com, with full terms of use and disclaimers accessible at https://www.InvestorWire.com/Disclaimer. The progress in ENV-105 development represents a meaningful step forward in addressing one of oncology's persistent challenges: treatment resistance that renders effective therapies ineffective over time.